Novo Nordisk has announced plans to move its ziltivekimab into phase 3 clinical development in atherosclerosis with chronic kidney disease after ... or heart failure. Data were announced at ...

Prevalence of cognitive impairment and dementia in people with kidney disease is disproportionately high, and improved detection is needed. Implementing routine screening for dementia in people ...